(Q36373370)

13 August 2017

1 reference

title

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy (English)

1 reference

13 August 2017

0 references

8

Laurence Zitvogel

0 references

Guido Kroemer

9

Guido Kroemer

0 references

Lorenzo Galluzzi

2

Lorenzo Galluzzi

0 references

Catherine Sautès-Fridman

6

Catherine Sautès-Fridman

0 references

Alexander Eggermont

3

Alexander Eggermont

0 references

Jérôme Galon

5

Jerome Galon

0 references

Erika Vacchelli

1

Erika Vacchelli

0 references

Eric Tartour

7

Eric Tartour

0 references

Wolf Hervé Fridman

4

Wolf Hervé Fridman

0 references

publication date

1 September 2012

1 reference

13 August 2017

1 reference

13 August 2017

1

1 reference

13 August 2017

894-907

1 reference

13 August 2017

6

1 reference

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Trial Watch: Immunostimulatory cytokines

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Trial Watch: Adoptive cell transfer immunotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Trial watch: Chemotherapy with immunogenic cell death inducers

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Trial Watch: Monoclonal antibodies in cancer therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Edward jenner and the small pox vaccine

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

The secret ally: immunostimulation by anticancer drugs

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Treatment of multifocal Bowen's disease in immunocompromised women with surgery and topical imiquimod

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Plasmacytoid dendritic cells: one-trick ponies or workhorses of the immune system?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Imiquimod as an adjuvant treatment measure for desmoplastic trichoepithelioma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Sterile inflammation: sensing and reacting to damage

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Safety and Efficacy of Multiple 16-week Courses of Topical Imiquimod for the Treatment of Large Areas of Skin Involved with Actinic Keratoses

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Robert Koch and the ‘golden age’ of bacteriology

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Targeting Toll-like receptors: emerging therapeutics?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Monophosphoryl lipid A plus IFNgamma maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high cytolytic potential

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Identification of a primary target of thalidomide teratogenicity

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Involution of infantile haemangiomas after imiquimod 5% cream

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Cryosurgery during topical imiquimod: a successful combination modality for lentigo maligna

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Treatment of vulvar intraepithelial neoplasia with topical imiquimod

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Complete resolution of Paget disease of the vulva with imiquimod cream

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Treatment of lentigo maligna with imiquimod before staged excision

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Management of refractory early-stage cutaneous T-cell lymphoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Treatment of extramammary Paget disease with topical imiquimod cream: case report and literature review

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

The evolution of vertebrate Toll-like receptors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

An open label evaluation of the efficacy of imiquimod 5% cream in the treatment of recalcitrant subungual and periungual cutaneous warts

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guérin peptidoglycan

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Combined whole tumor cell and monophosphoryl lipid A vaccine improved by encapsulation in murine colorectal cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

The effects of 5% imiquimod cream on high-grade vulval intraepithelial neoplasia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Imiquimod 5% cream in the treatment of Bowen's disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a cox inhibitor, sulindac: potential applications for this combination of immunotherapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Therapeutic effect of a new synthetic lipid A analog (ONO-4007) on a tumor implanted at different sites in rats.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Therapeutic approaches to genital warts

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

A receptor kinase-like protein encoded by the rice disease resistance gene, Xa21

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Improving the efficacy of BCG immunotherapy by dose reduction

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Isolation of a nontoxic lipid A fraction containing tumor regression activity.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Effect of methanol extraction residue of Bacillus Calmette-Guerin in advanced Hodgkin's disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Phase-I study of intravenous modified lipid A.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Endotoxic glycolipid from a heptoseless mutant of Salmonella minnesota

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Biologically Active Endotoxins from Salmonella Mutants Deficient in O- and R-Polysaccharides and Heptose

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

In vitro transformation of mouse bone-marrow-derived (B) lymphocytes induced by the lipid component of endotoxin.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Immunotherapy for acute myelogenous leukaemia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Site of action of lipid A on mitochondria.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Synthetic lipid A with endotoxic and related biological activities comparable to those of a natural lipid A from an Escherichia coli re-mutant

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Pilot study of intravenous administration of the acid-treated Salmonella minnesota R595 (Re) in cancer patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Efficacy of S26308 against guinea pig cytomegalovirus infection

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Chemoimmunotherapy for disseminated malignant melanoma: a prospective randomized study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Controlled trial of methotrexate and Bacillus Calmette-Guérin therapy for advanced head and neck cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Combination chemotherapy plus methanol extracted residue of bacillus Calmette-Guérin or Corynebacterium parvum in stage III lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Chemoimmunotherapy of metastatic large bowel cancer.Nonspecific stimulation with BCG and levamisole

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Treatment of osteogenic sarcoma. I. Effect of adjuvant high-dose methotrexate after amputation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Effects of combined immunotherapy with levamisole and Bacillus Calmette-Guérin on immunocompetence of patients with squamous cell carcinoma of the cervix, head and neck, and lung undergoing radiation therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Immunostimulators induce granulocyte/macrophage colony-stimulating activity and block proliferation in a monocyte tumor cell line

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Regions of the Lipopolysaccharide of Pseudomonas aeruginosa Essential for Antitumor and Interferon-Inducing Activities

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

A gene complex controlling segmentation in Drosophila

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Maintenance of remission in acute myelogenous leukaemia by a mixture of B.C.G. and irradiated leukaemia cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Bacillus Calmette-Guerin immunotherapy for bladder cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Efficacy and safety of 5% imiquimod cream in treating patients with multiple superficial basal cell carcinomas

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Efficacy of imiquimod 5% cream for basal cell carcinoma in transplant patients

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Imiquimod as a possible treatment for keratoacanthoma.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Therapeutic response of a brother and sister with xeroderma pigmentosum to imiquimod 5% cream

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Infection of swine with Mycobacterium bovis as a model of human tuberculosis

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Efficacy of MER immunotherapy when added to a regimen of 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A Veterans Administration Surgical Oncology Group report

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy: A southwest oncology group study

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Suppression of Urethan-Induced Lung Adenomas in Mice Treated with Trehalose-6,6-Dimycolate (Cord Factor) and Living Bacillus Calmette Guérin

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Tumor Immunity Produced by the Intradermal Inoculation of Living Tumor Cells and Living Mycobacterium bovis (Strain BCG)

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Biochemical studies on lipopolysaccharides of Salmonella R mutants. 6. Investigations on the structure of the lipid A component.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Effect of BCG and allogeneic tumor cells on adenovirus type 12 tumorigenesis in mice.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Results of administering B.C.G. to patients with melanoma

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Biological activities of chemically synthesized partial structure analogues of lipid A.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Monophosphoryl lipid A obtained from lipopolysaccharides of Salmonella minnesota R595. Purification of the dimethyl derivative by high performance liquid chromatography and complete structural determination.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Establishment of dorsal-ventral polarity in the Drosophila embryo: genetic studies on the role of the Toll gene product.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Relationship between immune system and gram-negative bacteria. Acid-treated Salmonella minnesota R595 (Re) enhances immune responsiveness in patients with gynecologic malignancies.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Antitumor and antimicrobial activities of lipid A-subunit analogue GLA-27.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Adjuvant bacillus Calmette-Guérin therapy in non-Hodgkin's malignant lymphomas: long-term results of a randomized trial in a single institution

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Effect of cell wall skeleton and monophosphoryl lipid A adjuvant on the immunogenicity of a murine B16 melanoma vaccine

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Antitumor effect of synthetic derivatives of lipid A in an experimental model of colon cancer in the rat

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Effects of cytokines and R-837, a cytokine inducer, on UV-irradiation augmented recurrent genital herpes in guinea pigs

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Lipid A, the active part of bacterial endotoxins in inducing serum colony stimulating activity and proliferation of splenic granulocyte/macrophage progenitor cells

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Skeletal and soft tissue sarcomas. Treatment with adjuvant immunotherapy

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Intralesional BCG in the treatment of metastatic malignant melanoma

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Molecular Genetics of the Bithorax Complex in Drosophila melanogaster.

28 June 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

From the analyst's couch: TLR-targeted therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Easter

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Optimization of intracerebral tumour protection by active-specific immunization against murine melanoma B16/G3.12.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Induction of intratumoral tumor necrosis factor by a synthetic lipid A analog, ONO-4007, with less tolerance in repeated administration and its implication in potent antitumor effects with low toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Effects of therapy with an immunomodulator (imiquimod, R-837) alone and with acyclovir on genital HSV-2 infection in guinea-pigs when begun after lesion development

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Treatment of genital warts with an immune-response modifier (imiquimod).

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Treatment of external genital warts in men with imiquimod 2% in cream. A placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

A prospective self-controlled phase II study of imiquimod 5% cream in the treatment of infantile hemangioma

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Treatment of lentigo maligna with topical imiquimod.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

A pilot study of treatment of lentigo maligna with 5% imiquimod cream

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Treatment of Bowen's disease using a cycle regimen of imiquimod 5% cream

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Spontaneous regression of keratoacanthoma can be promoted by topical treatment with imiquimod cream

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Successful treatment of multiple filiform facial warts with imiquimod 5% cream in a patient infected by human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Medical treatment of nasal squamous papilloma with imiquimod cream.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Successful treatment of intranasal papillomata with imiquimod cream in a human immunodeficiency virus positive patient

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Detection of CD8+ T cell responses to human papillomavirus type 16 antigens in women using imiquimod as a treatment for high-grade vulval intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Treatment of undifferentiated vulvar intraepithelial neoplasia with 5% imiquimod cream: a prospective study of 12 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Preliminary results of 5% imiquimod cream in the primary treatment of vulva intraepithelial neoplasia grade 2/3.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow-up of a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Successful treatment of three cases of primary extramammary Paget's disease of the vulva with Imiquimod--proposal of a therapeutic schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Development of Kaposi's sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara).

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Successful treatment of cutaneous hemangioma of infancy with topical imiquimod 5%: a report of 3 cases.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Imiquimod in vulvar Paget's disease: a case report.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Treatment of dysplastic nevi with 5% imiquimod cream, a pilot study.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Mycobacterium bovis tuberculosis: from animal to man and back.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Topical treatment with imiquimod may induce regression of facial keratoacanthoma

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Treatment of non-genital warts with topical imiquimod 5% cream.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Cytokine induction in mice by the immunomodulator imiquimod.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Lipid A and immunotherapy.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Immunotherapy for chronic myelogenous leukemia: survival not affected by treatment in the stable phase

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormono-immuno-versus hormonotherapy. Preliminary report of immunological and clinical aspects.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489745

Immunotherapy of ovarian cancer with cell wall skeleton ofMycobacterium bovisBacillus Calmette-Guérin: Effect of lymphadenectomy

21 October 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Low Dose Pasteur Bacillus Calmette-Guerin Regimen in Stage T1, Grade 3 Bladder Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Stimulation Of Non-Specific Immunity by the ‘Lipid A’ Component of Bacterial Lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

Cellular Requirements for Cytokine Production in Response to the Immunomodulators Imiquimod and S-27609

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FONCI.20931

The chemical constitution of lipid A from Serratia marcescens

21 January 2018

1 reference

12 December 2020

Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double-blinded study

1 reference

12 December 2020

Combined immunotherapy in malignant melanoma. Regression of metastatic lesions in two patients concordant in timing with systemic administration of transfer factor and Bacillus Calmette-Guérin

1 reference

12 December 2020

Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL

1 reference

12 December 2020

Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma

1 reference

12 December 2020

Comparison of chemotherapy with immunotherapy for maintenance of acute lymphoblastic leukemia in children and adults

1 reference

12 December 2020

A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mi

1 reference

12 December 2020

Active specific immunotherapy of Dukes B2 and C colorectal carcinoma: comparison of two doses of the vaccine

1 reference

12 December 2020

Bacillus calmette-guerin (BCG) adjuvant therapy in stage D prostate cancer

1 reference

12 December 2020

Efficacy of Imiquimod Cream, 5%, for Lentigo Maligna After Complete Excision

1 reference

12 December 2020

Role of lipid A of endotoxin in the production of tumour necrosis factor

1 reference

12 December 2020

Follow-up adjuvant chemotherapy and chemoimmunotherapy for stage II and III carcinoma of the breast

1 reference

12 December 2020

Treatment of disseminated malignant melanoma with high-dose oral BCG

1 reference

12 December 2020

[Study on the antineoplastic action of the bacterial lipid, "lipid A".]

1 reference

12 December 2020

Investigations on the mechanism of stimulation of non-specific immunity by bacterial lipopolysaccharides

1 reference

12 December 2020

TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG

1 reference

12 December 2020

Antitumor effect of DT-5461a, a synthetic low-toxicity lipid A analog, involves endogenous tumor necrosis factor induction subsequent to macrophage activation

1 reference

12 December 2020

Combined effects of synthetic lipid A analogs and muramyl dipeptide on antitumor activity against Meth A fibrosarcoma in mice

1 reference

12 December 2020

Intratumoral tumor necrosis factor induction and tumor growth suppression by ONO-4007, a low-toxicity lipid A analog

1 reference

12 December 2020

Adjuvant endocrine therapy, cytotoxic chemotherapy and immunotherapy in stage II breast cancer: 6-year result

1 reference

12 December 2020

Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage-II breast cancer: Five-year results

1 reference

12 December 2020

Conservative management of extramammary paget disease with imiquimod

1 reference

12 December 2020

Biological activities of chemically synthesized analogues of the nonreducing sugar moiety of lipid A.

1 reference

12 December 2020

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

1 reference

12 December 2020

Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). The Prudente Foundation Melanoma Study Group

1 reference

12 December 2020

Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide

1 reference

12 December 2020

A pilot study on the effect of BCG vaccination in patients with bronchial carcinoma

1 reference

12 December 2020

Bacillus Calmette-Guérin immunotherapy in ovarian cancer

1 reference

12 December 2020

Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer of the Dukes' C classification. Preliminary clinical results

1 reference

12 December 2020

Cytokine induction by the immunomodulators imiquimod and S-27609

1 reference

12 December 2020

Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer a prospective randomized trial

1 reference

12 December 2020

A new synthetic lipid A analog, ONO-4007, stimulates the production of tumor necrosis factor-alpha in tumor tissues, resulting in the rejection of transplanted rat hepatoma cells

1 reference

12 December 2020

Oral or intravesical bacillus Calmette-Guerin immunoprophylaxis in bladder carcinoma

1 reference

12 December 2020

Effect of administration of BCG, levamisole and irradiated leukemic cells on immune status and remission status in chronic myelogenous leukemia

1 reference

12 December 2020

Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study

1 reference

12 December 2020

Introducing HPV vaccine in developing countries--key challenges and issues

1 reference

12 December 2020

A trial of bacillus Calmette-Guérin versus adriamycin in superficial bladder cancer: a South-West Oncology Group Study

1 reference

12 December 2020

Kinetics of tumor cell apoptosis and immune cell activation during the regression of tumors induced by lipid A in a rat model of colon cancer

1 reference

12 December 2020

Topical imiquimod as treatment for different kinds of cutaneous lymphoma

1 reference

12 December 2020

Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum

1 reference

12 December 2020

Intermittent combination chemotherapy with or without bacillus Calmette-Guérin for treatment of acute lymphoblastic leukemia of childhood

1 reference

12 December 2020

Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results

1 reference

12 December 2020

Results of long-term follow-up of patients with superficial bladder carcinoma treated with intravesically applied bacillus Calmette-Guerin vaccine according to the schedule of 6 weekly + 6 monthly instillations

1 reference

12 December 2020

Adjuvant Therapy of Colon Cancer — Results of a Prospectively Randomized Trial

1 reference

12 December 2020

Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities

1 reference

12 December 2020

Randomized trial of Bacillus Calmette-Guérin (percutaneous administration) as surgical adjuvant immunotherapy for patients with stage-II melanoma

1 reference

12 December 2020

Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Guérin (BCG), and DTIC + corynebacterium parvum in advanced malignant melanoma. W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanom

1 reference

12 December 2020

A phase II evaluation of bacillus calmette-guerin plus megestrol acetate in patients with metastatic renal adenocarcinoma

1 reference

12 December 2020

1 reference

12 December 2020

Treatment of acute lymphoblastic leukaemia. Comparison of immunotherapy (B.C.G.), intermittent methotrexate, and no therapy after a five-month intensive cytotoxic regimen ((Concord trial). Preliminary report to the Medical Research Council by the Le

1 reference

12 December 2020

Immunostimulation with intrapleural BCG as adjuvant therapy in resected non-small cell lung cancer. The Ludwig Lung Cancer Study Group (LLCSG)

1 reference

12 December 2020

Assessment of tamoxifen as adjuvant therapy in stage II breast cancer: a long-term follow-up

1 reference

12 December 2020

Management of adult acute leukemia. A Southwest Oncology Group study

1 reference

12 December 2020

Studies on the anti-tumor effect of the bacterial lipid component, lipid A. I. On some physicochemical properties and antitumor activity of lipid A fraction

1 reference

12 December 2020

Intravesical Bacillus Calmette-Guérin prophylactic treatment for superficial bladder tumors: results of a controlled prospective study

1 reference

12 December 2020

A trial of adjuvant combination chemoimmunotherapy for stage III carcinoma of stomach

1 reference

12 December 2020

Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma

1 reference

12 December 2020

A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions

1 reference

12 December 2020

PURIFICATION AND CHARACTERIZATION OF THE LIPID A COMPONENT OF THE LIPOPOLYSACCHARIDES FROM ESCHERICHIA COLI

1 reference

12 December 2020

Imiquimod 5% cream for the treatment of nasal lesion of metastatic renal cell carcinoma

1 reference

12 December 2020

Structural features of lipid A preparations isolated from Escherichia coli and Shigella flexneri

1 reference

12 December 2020

A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report

1 reference

12 December 2020

Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma

1 reference

12 December 2020

The Side Effects of Bacillus Calmette-Guerin in the Treatment of Ta T1 Bladder Cancer Do Not Predict its Efficacy: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial

1 reference

12 December 2020

Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy

1 reference

12 December 2020

The use of bacillus Calmette-Guerin in the therapy of bladder carcinoma in situ

1 reference

12 December 2020

Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma

1 reference

12 December 2020

Role of lipid A in the production of tumor necrosis factor and differences in antitumor activity between tumor necrosis factor and lipopolysaccharide

1 reference

12 December 2020

Antitumor effect of DT-5461, a lipid A derivative, against human tumor xenografts is mediated by intratumoral production of tumor necrosis factor and affected by host immunosuppressive factors in nude mice

1 reference

12 December 2020

Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects

1 reference

12 December 2020

Topical treatment of cutaneous Kaposi sarcoma with imiquimod 5% in renal-transplant recipients: a clinicopathological observation

1 reference

12 December 2020

QS-21: a water-soluble triterpene glycoside adjuvant

1 reference

12 December 2020

Combined BCG and irradiation treatment of skin metastases originating from malignant melanoma

1 reference

12 December 2020

Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma

1 reference

12 December 2020

Experience with intravesical bacillus Calmette-Guèrin therapy of superficial bladder tumors

1 reference

12 December 2020

Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule

1 reference

12 December 2020

A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study

1 reference

12 December 2020

Immunotherapy of prostatic carcinoma with bacillus Calmette-Guerin

1 reference

12 December 2020

Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guérin

1 reference

12 December 2020

Multicenter study of superficial bladder cancer treated with intravesical bacillus Calmette-Guerin or adriamycin. Results of long-term follow-up

1 reference

12 December 2020

Bladder cancer immunotherapy

1 reference

12 December 2020

Imiquimod in clinical practice

1 reference

12 December 2020

Bacillus Calmette-Guerin in the Treatment of Adenocarcinoma of the Kidney

1 reference

12 December 2020

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

1 reference

12 December 2020

Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton. 3- to 6-year follow up of a randomized clinical trial

1 reference

12 December 2020

Effects of a new synthetic lipid A on endogenous tumor necrosis factor production and antitumor activity against human pancreatic cancer cells

1 reference

12 December 2020

Cytoreductive surgery and systemic bacillus Calmette-Guerin therapy in metastatic renal cancer: a phase II trial

1 reference

12 December 2020

Biological activities of analogues of lipid A based chemically on the revised structural model. Comparison of mediator-inducing, immunomodulating and endotoxic activities

1 reference

12 December 2020

Success of HPV vaccination is now a matter of coverage

1 reference

12 December 2020

Adjuvant immunotherapy (BCG) in stage D prostate cancer

1 reference

12 December 2020

Imiquimod: a novel treatment for lentigo maligna

1 reference

12 December 2020

Experimental percutaneous renal embolization using BCG-saturated gelfoam

1 reference

12 December 2020

Active specific immunotherapy of stage IV renal carcinoma with aggregated tumor antigen adjuvant

1 reference

12 December 2020

Treatment of acute myelogenous leukemia: influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy

1 reference

12 December 2020

FLS2: an LRR receptor-like kinase involved in the perception of the bacterial elicitor flagellin in Arabidopsis

1 reference

12 December 2020

Identifiers

DOI

10.4161/ONCI.20931

1 reference

13 August 2017

1 reference

13 August 2017

1 reference

PMCID

3489745